Although the literature on the population-specific incidence rate of the BRCA1/2 mutation is scarce, a preliminary study by Petrovics et al (2016)43 identified pathogenic mutations and variants of uncertain significance (VUSs) in 7.3% of African-American patients with prostate cancer versus 2.2% of NHW patients. This evidence concerns the gene BRCA1 and prostate cancer.